Advertisement

Utilize the full potential of real world evidence

  • Author Footnotes
    1 Vascular Center Darmstadt, Klinikum Darmstadt GmbH, Grafenstraße 9, d-64283 Darmstadt, Germany
    Rupert Bauersachs
    Footnotes
    1 Vascular Center Darmstadt, Klinikum Darmstadt GmbH, Grafenstraße 9, d-64283 Darmstadt, Germany
    Affiliations
    Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany
    Search for articles by this author
  • Author Footnotes
    1 Vascular Center Darmstadt, Klinikum Darmstadt GmbH, Grafenstraße 9, d-64283 Darmstadt, Germany
Published:October 07, 2020DOI:https://doi.org/10.1016/j.ejim.2020.10.008
      After the pivotal phase 3 trials on venous thromboembolism (VTE) treatment with non-vitamin K antagonist oral anticoagulants (NOACs) had been performed some 10 years ago, these drugs have now become the standard anticoagulant treatment of VTE. While randomized controlled trials (RCT) carefully select patients to allow homogeneous comparisons between the randomized groups, real world evidence (RWE) is required from a much larger patient population with a high variation of clinical characteristics. Therefore, it is crucial to ensure that the efficacy and safety observed in phase 3 trials can be confirmed in everydays clinical settings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cohen A.T.
        • Hoffmann U.
        • Hainaut P.
        • et al.
        ETNA VTE Europe: a contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.
        Eur J Intern Med. 2020;
        • Buller H.R.
        • Decousus H.
        • Grosso M.A.
        • et al.
        Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
        N Engl J Med. 2013; 369: 1406-1415
        • Bauersachs R.
        • Agnelli G.
        • Gitt A.K.
        • et al.
        The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry.
        Thromb Res. 2017; 157: 181-188
        • Schellong S.M.
        • Goldhaber S.Z.
        • Weitz J.I.
        • et al.
        Isolated distal deep vein thrombosis: perspectives from the GARFIELD-VTE registry.
        Thromb Haemost. 2019; 19: 1675-1685
        • Cohen A.T.
        • Gitt A.K.
        • Bauersachs R.
        • et al.
        The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE registry.
        Thromb Haemost. 2017; 117: 1326-1337
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Monreal M.
        • Suarez C.
        • Fajardo J.A.
        • et al.
        Management of patients with acute venous thromboembolism: findings from the RIETE registry.
        Pathophysiol Haemost Thromb. 2003; 33: 330-334
        • Ageno W.
        • Mantovani L.G.
        • Haas S.
        • et al.
        Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
        Lancet Haematol. 2016; 3: e12-e21
        • Ageno W.
        • Casella I.B.
        • Han C.K.
        • et al.
        Re-covery DVT/PE: rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
        Thromb Haemost. 2017; 117: 415-421
        • Weitz J.I.
        • Haas S.
        • Ageno W.
        • et al.
        Global anticoagulant registry in the field – venous thromboembolism (GARFIELD-VTE). Rationale and design.
        Thromb Haemost. 2016; 116: 1172-1179
        • Cohen A.T.
        • Ay C.
        • Hainaut P.
        • et al.
        Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thrombo embolism in Europe (ETNA-VTE-Europe) study.
        Thromb J. 2018; 16: 9
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • et al.
        Apixaban for extended treatment of venous thromboembolism.
        N Engl J Med. 2012; 368: 699-708
        • Weitz J.I.
        • Lensing A.W.
        • Prins M.H.
        • et al.
        Rivaroxaban or aspirin for extended treatment of venous thromboembolism.
        N Engl J Med. 2017; 376: 1211-1222
        • Schulman S.
        • Kearon C.
        • Kakkar A.K.
        • et al.
        Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.
        N Engl J Med. 2013; 368: 709-718
        • De Caterina R.
        • Kelly P.
        • Monteiro P.
        • et al.
        Design and rationale of the edoxaban treatment in routine clinical practice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study.
        J Cardiovasc Med (Hagerstown). 2019; 20: 97-104

      Biography

      Dr. Bauersachs reports personal fees from Bristol Myers Squibb, personal fees from Bayer AG, personal fees from Daichii-Sankyo, personal fees from Leo Pharma, all outside the submitted work.